There is little evidence on treatment strategy for postoperative locoregional relapsed nonesmall-cell lung cancer. Seventy-four consecutive patients with nonesmall-cell lung cancer with postoperative locoregional recurrences who received chemoradiotherapy (CRT) or radiotherapy at our institute were analyzed. Multivariate analysis identified CRT as a significant survival factor. CRT showed favorable survival outcomes with acceptable feasibility of both CRT and radiotherapy. Background: The optimal treatment strategy for locoregional recurrences developing after surgical resection in patients with nonesmall-cell lung cancer (NSCLC) is yet to be clearly established. Patients and Methods: To investigate the efficacy and safety of radiotherapy (RT) and chemoradiotherapy (CRT), we reviewed the consecutive data of patients with NSCLC with postoperative locoregional recurrences treated at the National Cancer Center Hospital between January 2000 and April 2010. Results: We reviewed the data of 74 patients (including 56 who received RT alone and 18 who received CRT) according to our study criteria. The median age was lower and the N factor at the recurrence site was higher in the CRT group compared with the RT group. Most patients received 60 Gy/30 Fr RT in both groups. The 2-year progression-free survival (PFS) rate, median PFS, and overall survival (OS) were 44.4%, 19.0 months (95% confidence interval [CI], 0-41.9 months), and 79.6 months (95% CI, 8.2-151.0 months), respectively, in the CRT group, although those were 25.0%, 10.6 months (95% CI, 8.7-12.9 months), and 33.1 months (95% CI, 17.9-48.3 months), respectively, in the RT group. The adverse event profile was acceptable, with no treatment-related death in either group. Multivariate analysis identified CRT as being significantly associated with a longer PFS and OS. Conclusion: CRT tended to yield better results than RT in terms of the survival outcomes, with acceptable safety profiles of both. We consider that a randomized study comparing RT and CRT is warranted to identify the optimal treatment strategy for patients with NSCLC with postoperative locoregional recurrences.
Introduction
Nonesmall-cell lung cancer (NSCLC) accounts for approximately 85% of all types of lung cancer. 1 Surgery is the standard treatment method for patients with resectable NSCLC. 2, 3 Even after considered that there is a constant frequency of locoregional recurrence alone and the proportion varies from 8% to 37%. 4, [7] [8] [9] [10] [11] Radiotherapy (RT) has often been selected for the treatment of local recurrences developing after complete resection and has been reported to yield good local response rates and prolongation of survival. [12] [13] [14] [15] [16] On the other hand, chemoradiotherapy (CRT) has also been selected, in accordance with the treatment strategy for unresectable Stage III NSCLC. 6, 17 Concurrent CRT is the standard treatment strategy employed in patients with a good performance status (PS). [18] [19] [20] [21] However, the optimal treatment strategy for locoregional recurrences is yet to be clearly established, because no prospective clinical trials have been reported so far. Besides the need to precisely evaluate the efficacy and adverse events (AEs) of RT and CRT, it is also important to identify the relevant prognostic factors. The purpose of this study was to explore the optimal treatment strategy for locoregional recurrences developing after surgical resection in patients with NSCLC.
Patients and Methods

Patient Selection
We reviewed the consecutive data of patients with NSCLC who were treated at our hospital between January 2000 and April 2010 for any recurrences developing after curative surgery.
Postoperative recurrence was confirmed by one or both of computed tomography (CT) and 18F-fluorodeoxyglucose positron emission tomography-computed tomography (PET-CT), or by histopathologic diagnosis (biopsy). We carried out a retrospective review of the medical records of these patients after obtaining approval of the protocol from the institutional review board of the National Cancer Center Hospital (number: 2012-180).
We defined locoregional recurrence after curative surgery as recurrence only at the local site (the bronchial stump and adjacent areas) or also in the regional lymph node (ipsilateral hilar lymph nodes, mediastinal lymph nodes, and supraclavicular lymph nodes). Recurrence in the contralateral hilar lymph nodes and separate tumor nodule(s) in a different ipsilateral lobe were labeled as distant metastases and not included as locoregional recurrences.
Patients with NSCLC with locoregional recurrences who had been treated by RT or CRT with curative intent were considered as eligible and included for the analyses in our study. Patients diagnosed as having large-cell neuroendocrine carcinoma were excluded. We also excluded patients who had received chemotherapy alone, stereotactic external-beam radiation therapy, or some treatment details of which were unknown, or had synchronous multiple primary cancers.
Data Collection
The baseline patient characteristics at the start of the treatment for locoregional recurrence were collected from the medical records. Data collected included the age, Eastern Cooperative Oncology Group PS, gender, histologic type, pathologic stage according to the seventh edition of the TNM classification proposed by the Union RT or CRT for Locoregional Recurrence of NSCLC for International Cancer Control, history of adjuvant chemotherapy, time to recurrence after surgery, and the site of recurrence (T and N factors based on the primary lesion before the surgery). Data regarding treatment were also collected, including the radiation dose, timing of RT in relation to the chemotherapy (concurrent or sequential), the chemotherapy regimen used and total number of chemotherapy cycles administered, and also the AEs (febrile neutropenia, esophagitis, early and late pulmonary toxicities, and other nonhematologic AEs).
Treatment
The treatment for patients with NSCLC with locoregional recurrence developing after resection for the primary tumor was selected by discussion among oncology experts, including the medical oncologist, thoracic surgeon, and radiation oncologist. Thoracic RT with curative intent was delivered with from a megavoltage equipment ( 6 MV) by 3-dimensional planning, and provided for the lung lesions, the metastatic lymph nodes, and the regional nodes, followed by additional booster RT for the lung lesion and metastatic lymph nodes. Platinum-based combination chemotherapy was administered with the RT.
All the patients in our study were periodically followed-up at our outpatient department at least once every 3 months after the start of treatment for locoregional recurrence. We conducted systemic surveillance at the follow-up examinations by performing chest xray, CT, magnetic resonance imaging, and PET-CT according to the consensus at our single facility specialized in cancer, at least once in 3 months within the first year of follow-up and once every 6 months thereafter.
Efficacy and Toxicity Evaluation
The objective tumor response to the treatment was determined according to the Response Evaluation Criteria for Solid Tumors (RECIST), version 1.1. Progression-free survival (PFS) was calculated from the day of start of treatment for the locoregional recurrence to the day of detection of re-recurrence or the day of death from any cause. Overall survival (OS) was calculated as the time from the start of treatment for locoregional recurrence to the last date of confirmation of survival or the date of death from any cause. The data cutoff date was April 30, 2015.
Toxicity data was graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events, 
Shinji Nakamichi et al
Clinical Lung Cancer November 2017 -e443 version 4.0. Late pulmonary toxicities occurring as a result of RT were defined as those that occurred later than or persisted for 90 days after the completion of RT and were graded according to the late radiation morbidity scoring scheme of the Radiation Therapy Oncology Group/European Organization for Research and Treatment of Cancer. 22 
Statistical Analysis
Differences in the patient characteristics at the start of treatment between the RT and CRT groups were analyzed using the Fisher exact test and the Mann-Whitney U test. The PFS and OS were calculated using the Kaplan-Meier method. To investigate the association of any patient characteristics at the start of treatment for the locoregional recurrence with the survival, the Cox proportional hazard model was used. The variables examined were the age (< 70 vs. 70 years), gender, histology (adenocarcinoma vs. squamous cell carcinoma), time in months to recurrence ( 24 vs. < 24), recurrence site (N0-2 vs. with N3), and treatment method employed (RT vs. CRT). All statistical analyses were performed using IBM SPSS, version 21.0.
Results
Patient Characteristics
From January 2000 to April 2010, 251 patients with NSCLC who developed recurrence after curative surgery were treated at our hospital. Of these patients, we identified 98 (39%) as having locoregional recurrence alone, whereas the remaining 153 had distant metastasis. Of 98 patients with locoregional recurrence, 11 patients with large-cell neuroendocrine carcinoma, 5 patients who had received chemotherapy alone, 2 patients who had received stereotactic external-beam radiation therapy, 4 patients who had received treatment of which the details were unknown, and 2 patients with simultaneous multiple primary cancers were excluded from our study. Finally, the data of 74 patients with locoregional recurrences who had been treated by RT or CRT with curative intent were analyzed in our study (shown in Figure 1 ). Of the 74 patients, 56 had received RT alone, and 18 had received CRT. The baseline characteristics were as follows (Table 1) : overall patient population: median age, 66 years (range, 41-85 years); male/female ratio, 57/17; adeno/squamous histology, 49/25; RT group: median age, 68 years (range, 46-85 years); male/female ratio, 41/15; adeno/ squamous histology, 39/17; CRT group: median age, 61 years (range, 41-73 years); male/female ratio, 5/13; adeno/squamous histology, 10/8. The CRT group had a significantly higher proportion of younger patients than the RT group. Adjuvant chemotherapy followed by curative surgery had been undertaken in 8 patients of the RT group. Three patients had received platinum-based chemotherapy, and 5 patients had received tegafur/uracil. On the other hand, none of the patients had received adjuvant chemotherapy in the CRT group. Eight patients in whom the recurrence was detected 60 months or later after the surgery were judged as having locoregional recurrences on the basis of the clinical course and results of various examinations performed by the investigators.
Treatment Delivery
The details of the treatment delivery are shown in Table 2 . RT was completed in all 74 eligible patients. Of the 56 patients in the RT group, 53 patients (95%) had received 2 Gy/fraction/day on 5 days/week up to 60 Gy/30 fractions. Two patients had received 50 Gy radiation for radical treatment after taking into consideration the large radiation field and the pulmonary function. One patient with a tracheal stent received 70 Gy, taking into account scattering of radiation. We included these patients who received 50 or 70 Gy radiation as eligible in this study, because they received a curative radiation dose. All patients in the CRT group had also received 60 Gy RT, just as in the RT group. In the CRT group, 13 patients had 
Total number of chemotherapy Cycles , administered every 4 weeks. In the patients who had received concurrent CRT, the chemotherapy regimen was CDDP and VNR in all the patients. One-half (9/18) of these patients had received consolidation chemotherapy after concurrent CRT.
Response and Survival
In the overall patient population, the response rate (RR) was 70%; the complete response (CR) rate was 17%, and the partial response (PR) rate was 53%. In the RT group, the RR was 68% (CR rate, 16%; PR rate, 52%). In the CRT group, the RR was 78% (CR rate, 22%; PR rate, 56%). The 2-year PFS rate, 2-year survival rate, and 5-year survival rate were 30%, 62%, and 37% in total 
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Clinical Lung Cancer November 2017 -e445 patients; 25%, 55%, and 35% in the RT group; and 44%, 82%, and 53% in the CRT group, respectively ( Table 3) . The median PFS rates in the overall patient population, the RT group, and the CRT group were 11.6 months (95% confidence interval [CI], 9.0-14.2 months), 10.6 months (95% CI, 8.7-12.9 months), and 19.0 months (95% CI, 0-41.9 months), respectively (Figure 2A and B) . The median OS rates in the overall patient population, the RT group, and the CRT group were 34.4 months (95% CI, 25.2-43.6 months), 33.1 months (95% CI, 17.9-48.3 months), and 79.6 months (95% CI, 8.2-151.0 months), respectively ( Figure 2C and D) .
Toxicities
The AEs are summarized in Table 4 . Three cases (5%) and 1 case (5%) of grade 3 early radiation pneumonitis were observed in the RT group and the CRT group, respectively. One case (2%) of late radiation pneumonitis was observed in the RT-alone group. Three cases (17%) of grade 3 febrile neutropenia were observed among the patients who had received CRT with CDDP and VNR. In regard to the nonhematologic AEs, there were 2 cases of grade 1 radiation dermatitis, 1 case of grade 2 creatinine elevation, and 1 case of grade 3 anorexia in the RT group, and 2 cases of grade 1 radiation dermatitis, 1 case of grade 2 creatinine elevation, and 1 case of grade 3 anemia in the CRT group. There were no cases of treatmentrelated death in either the RT or the CRT group.
Evaluation of Prognostic Factors
Based on the results of multivariate analysis carried out using a Cox proportional hazards model with adjustments for factors previously described, female gender, the N factor at the site of recurrence, and CRT were identified as being significantly associated with a longer PFS and OS. In patients who had received CRT, the adjusted hazard ratio for the PFS and OS were as follows: PFS, 0.43 (95% CI, 0.21-0.86) and OS, 0.43 (95% CI, 0.19-0.97) (shown in Table 5 ).
Discussion
To the best of our knowledge, ours is the largest and most detailed consecutive data analysis of RT and CRT in patients with NSCLC with locoregional recurrences developing after radical operation. CRT tended to yield a longer PFS and OS than RT with acceptable safety profiles of both. Furthermore, multivariate analysis also identified CRT as a significant factor associated with a longer PFS and OS, even after adjustments for confounding factors.
The PFS and OS tended to be better in the CRT group than in the RT group in our analysis. There is no previously published report directly comparing the safety and efficacy of RT and CRT. In both groups, almost all patients received RT at 60 Gy/30 Fr. We could not clearly unravel the clinical significance of chemotherapy administered in addition to RT in the patients with locoregional recurrences. As in the case of treatment for stage III NSCLC, chemotherapy might be effective to increase the local control by RT and reduce the rate of development of distant metastasis. 23 On the basis of our findings, we suggest that CRT may be a promising treatment method for patients with NSCLC developing locoregional recurrences after resection surgery. However, there are no results of any prospective randomized trials, probably because number of patients with limited-extent local recurrence eligible for clinical trial is relatively small. Similar to other reports, treatment selection was affected by patients' characteristics in this retrospective analysis based on clinical practice. There is a possibility that PS affected treatment selection, because CRT tended to be selected in patients with PS 0. RT also tended to be selected in patients with higher age. On the other hand, CRT tended to be selected in patients with extensive lymph node metastases. Although treatment selection could have some effect on the result of the analysis, patients who received CRT experienced better treatment course even after extensive lymph nodes recurrence. Based on this finding, a prospective randomized trial comparing CRT and RT in patients groups with well-balanced characteristics is warranted.
AEs associated with RT and CRT for locoregional recurrences have not been clearly reported in previous articles. Although grade 3 early radiation pneumonitis was observed in 5% of cases of both the RT and CRT groups in our study, these results are similar to previously reported results of RT and CRT for Stage III unresectable NSCLC. 18, 21, [24] [25] [26] [27] As compared with the RT group, the frequency of febrile neutropenia and esophagitis was higher in the CRT group. These results are also similar to previous reports of the results of RT/ CRT for Stage III unresectable NSCLC. From the results of our analysis, it would appear that both RT and CRT are safe and feasible treatment options. Our study had several limitations. First, there were differences in the baseline patient characteristics and treatment details (eg, imbalance of PS, frequency in adjuvant chemotherapy, and extent of lymph nodes metastasis) between RT and CRT because of its retrospective nature. However, the consecutive data were reviewed without exclusion of unfavorable data. We considered our results were highly objective and close to our clinical practice. Second, we could not evaluate laboratory examination-based AEs thoroughly (for example, neutropenia, leukocytopenia, and anemia) because the follow-up examinations were not carried out in a uniform manner as in a prospective clinical trial. Third, adjuvant cisplatin-based chemotherapy for Stage II and III NSCLC might affect the choice of the treatment method. 28, 29 Adjuvant chemotherapy was not employed in the first half of our study period, because its effect on the survival had not been revealed at that time. Fourth, the criteria for selection of treatment whether CRT or RT was not decided clearly. CRT had a tendency to be selected in patients with younger age and more extensive N factor by discussion of oncologic experts at our hospital. It was considered to be important that CRT resulted in better PFS and OS in spite of more extensive N factors.
Conclusion
CRT tended to yield better survival outcomes than RT with an acceptable AE profile of both, in patients with NSCLC with locoregional recurrence after complete surgery included in this study. Further studies are warranted to clarify the optimal treatment strategy for patients with NSCLC presenting with locoregional recurrence after resection surgery for the primary tumor.
Clinical Practice Points
Locoregional recurrences developing after surgical resection in patients with NSCLC are said to occur occasionally. However, the optimal treatment method for postoperative local relapses has not been clearly established yet.
RT or CRT has been often selected for patients with NSCLC with postoperative locoregional recurrences developing after surgery. Although several articles with a small number of patients have been reported, no prospective study has been conducted so far. In this analysis, we precisely evaluated the efficacy and AEs of RT and CRT using data from a total of 74 consecutive patients at our institute from 2000 to 2010. We also examined the prognostic factors influencing the PFS and OS by multivariate analysis. We obtained the following outcomes who received RT or CRT, respectively: 2-year PFS rate: 25.0% and 44.0%; median PFS: 10.6 and 19.0 months; and median OS: 33.1 and 79.6 months. The AEs were feasible in both RT and CRT. Multivariate analysis identified CRT as a being independent prognostic factor for longer PFS and OS. Based on our findings, CRT showed better outcomes than RT in terms of the survival outcomes with the favorable feasibility of both in our analysis. We suggest that a randomized study comparing RT and CRT is warranted for patients with NSCLC with postoperative locoregional recurrences.
